FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387477465> ?p ?o ?g. }

• W4387477465 abstract "Aims/hypothesis Glucagon-like peptide 1 (GLP-1) agonists and sodium-glucose co-transporter-2 (SGLT2) inhibitors are novel drugs which have recently seen rapid uptake in the treatment of type 2 diabetes and obesity. The paucity of data regarding their safety during pregnancy and lactation causes a dilemma for the physician. The aim of the present study was to systematically review all available data on the offspring effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation. Methods We systematically searched PubMed, clinicaltrials.gov, FDA and EMA product information on GLP-1 agonists and SGLT2 inhibitors in pregnancy and lactation from inception up to 19 April 2022 without language restrictions. We approached both the Netherlands Pharmacovigilance Centre Lareb on January 17 th 2023 and the Teratology Information Service (TIS) of Switzerland on February 6 th 2023. Eligible studies investigating the safety (including congenital anomalies, fetal growth, perinatal demise) in animals or humans, or reporting the degree of transfer of these drugs to the fetus, breast milk or breastfed neonate. Two reviewers independently assessed and selected studies for inclusion and subsequently resolved discrepancies by discussion. Results We included 39 records (n=9 theoretical; based on drug properties, n=7 human; n=23 animal, including 76 human offspring, and an unknown number of animal offspring as these numbers could not be retrieved from the FDA and EMA product information). In animal studies, GLP1-agonists were associated with reduced fetal weight and/or growth, delayed ossification and skeletal variants, usually associated with a reduction in maternal weight gain and decreased food consumption. Exendin-4 (GLP1-agonist) was not transported across the maternal-fetal placental interface. In human studies, exenatide (GLP1-agonist) showed a fetal-to-maternal peptide concentration ratio of ≤ 0.017 in ex vivo human placental perfusion in a single placenta. Liraglutide (GLP1-agonist) showed no significant maternal to fetal transfer at least 3.5 hours after maternal exposure in a human study with one subject. In animal studies, GLP-1 agonists were excreted in breast milk; human data on excretion were not available. In animal studies, SGLT2 inhibitors were generally safe during the first trimester but exposure during postnatal day 21 to 90 in juvenile rats, a period coinciding with the late second and third trimester of human renal development, caused dilatation of the renal pelvis and tubules. Human data consisted of a pharmaceutical database of inadvertent pregnancies during SGLT2 inhibitor use, which found an increase in miscarriages and congenital malformations. In animal studies SGLT2 inhibitors were excreted in breast milk and affected neonatal growth, but human data are not available. Conclusion/interpretation We found evidence for adverse offspring effects of GLP-1 agonists and SGLT2 inhibitors also in human studies. Our findings broadly support the advice to discontinue GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation, and also support the ongoing registration of pregnancy outcomes in pharmacological databases since the amount of available data is scarce and mostly limited to animal studies. Registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=219877" @default.
• W4387477465 created "2023-10-11" @default.
• W4387477465 creator A5022312007 @default.
• W4387477465 creator A5024619720 @default.
• W4387477465 creator A5044206273 @default.
• W4387477465 creator A5046947444 @default.
• W4387477465 creator A5051189993 @default.
• W4387477465 creator A5078094335 @default.
• W4387477465 date "2023-10-10" @default.
• W4387477465 modified "2023-10-16" @default.
• W4387477465 title "Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence" @default.
• W4387477465 cites W1681361632 @default.
• W4387477465 cites W1892323012 @default.
• W4387477465 cites W1894556530 @default.
• W4387477465 cites W1966284758 @default.
• W4387477465 cites W1975469422 @default.
• W4387477465 cites W1977849050 @default.
• W4387477465 cites W1982246457 @default.
• W4387477465 cites W1986742981 @default.
• W4387477465 cites W1991138106 @default.
• W4387477465 cites W1994302034 @default.
• W4387477465 cites W2017136862 @default.
• W4387477465 cites W2029550741 @default.
• W4387477465 cites W2036862728 @default.
• W4387477465 cites W2038554266 @default.
• W4387477465 cites W2048000124 @default.
• W4387477465 cites W2058571677 @default.
• W4387477465 cites W2061338007 @default.
• W4387477465 cites W2061617771 @default.
• W4387477465 cites W2097636587 @default.
• W4387477465 cites W2107887942 @default.
• W4387477465 cites W2115330378 @default.
• W4387477465 cites W2146264128 @default.
• W4387477465 cites W2158847005 @default.
• W4387477465 cites W2425644022 @default.
• W4387477465 cites W2614636769 @default.
• W4387477465 cites W2741227657 @default.
• W4387477465 cites W2795368662 @default.
• W4387477465 cites W2799518691 @default.
• W4387477465 cites W2807279220 @default.
• W4387477465 cites W2807429818 @default.
• W4387477465 cites W2808935929 @default.
• W4387477465 cites W2888321467 @default.
• W4387477465 cites W2902839751 @default.
• W4387477465 cites W2947002298 @default.
• W4387477465 cites W2984880247 @default.
• W4387477465 cites W3152706179 @default.
• W4387477465 cites W4205339595 @default.
• W4387477465 cites W4214574810 @default.
• W4387477465 doi "https://doi.org/10.3389/fendo.2023.1215356" @default.
• W4387477465 hasPublicationYear "2023" @default.
• W4387477465 type Work @default.
• W4387477465 citedByCount "0" @default.
• W4387477465 crossrefType "journal-article" @default.
• W4387477465 hasAuthorship W4387477465A5022312007 @default.
• W4387477465 hasAuthorship W4387477465A5024619720 @default.
• W4387477465 hasAuthorship W4387477465A5044206273 @default.
• W4387477465 hasAuthorship W4387477465A5046947444 @default.
• W4387477465 hasAuthorship W4387477465A5051189993 @default.
• W4387477465 hasAuthorship W4387477465A5078094335 @default.
• W4387477465 hasBestOaLocation W43874774651 @default.
• W4387477465 hasConcept C112672928 @default.
• W4387477465 hasConcept C126322002 @default.
• W4387477465 hasConcept C134018914 @default.
• W4387477465 hasConcept C172268261 @default.
• W4387477465 hasConcept C172680121 @default.
• W4387477465 hasConcept C2775950024 @default.
• W4387477465 hasConcept C2776659692 @default.
• W4387477465 hasConcept C2777180221 @default.
• W4387477465 hasConcept C2777451236 @default.
• W4387477465 hasConcept C2779234561 @default.
• W4387477465 hasConcept C2779434492 @default.
• W4387477465 hasConcept C46973012 @default.
• W4387477465 hasConcept C54355233 @default.
• W4387477465 hasConcept C555293320 @default.
• W4387477465 hasConcept C71924100 @default.
• W4387477465 hasConcept C86803240 @default.
• W4387477465 hasConceptScore W4387477465C112672928 @default.
• W4387477465 hasConceptScore W4387477465C126322002 @default.
• W4387477465 hasConceptScore W4387477465C134018914 @default.
• W4387477465 hasConceptScore W4387477465C172268261 @default.
• W4387477465 hasConceptScore W4387477465C172680121 @default.
• W4387477465 hasConceptScore W4387477465C2775950024 @default.
• W4387477465 hasConceptScore W4387477465C2776659692 @default.
• W4387477465 hasConceptScore W4387477465C2777180221 @default.
• W4387477465 hasConceptScore W4387477465C2777451236 @default.
• W4387477465 hasConceptScore W4387477465C2779234561 @default.
• W4387477465 hasConceptScore W4387477465C2779434492 @default.
• W4387477465 hasConceptScore W4387477465C46973012 @default.
• W4387477465 hasConceptScore W4387477465C54355233 @default.
• W4387477465 hasConceptScore W4387477465C555293320 @default.
• W4387477465 hasConceptScore W4387477465C71924100 @default.
• W4387477465 hasConceptScore W4387477465C86803240 @default.
• W4387477465 hasLocation W43874774651 @default.
• W4387477465 hasOpenAccess W4387477465 @default.
• W4387477465 hasPrimaryLocation W43874774651 @default.
• W4387477465 hasRelatedWork W2327349099 @default.
• W4387477465 hasRelatedWork W2373302420 @default.
• W4387477465 hasRelatedWork W2777035846 @default.
• W4387477465 hasRelatedWork W2781215378 @default.

• next